FindTrial
Sign In

IL2

DRUG6 trials

Sponsors

University of Washington, University of Wisconsin, Madison, Assistance Publique - Hôpitaux de Paris, Centre Hospitalier Universitaire de Nice, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Conditions

Alopecia AreataCurative ResectionHematopoietic Stem Cell TransplantationKidney CancerProstate CancerRelapsing Remitting Multiple SclerosisStage IV Colorectal Cancer

Phase 1

Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer
CompletedNCT00283829
University of WashingtonProstate Cancer
Start: 2002-09-30End: 2006-07-31Updated: 2007-11-29
Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant
CompletedNCT03862833
Nantes University HospitalHematopoietic Stem Cell Transplantation
Start: 2019-05-07End: 2023-08-29Updated: 2026-09-14

Phase 2

Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
TerminatedNCT00582790
University of Wisconsin, MadisonKidney Cancer
Start: 2003-08-31End: 2008-09-30Updated: 2019-11-25
Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
CompletedNCT02424396
Assistance Publique - Hôpitaux de ParisRelapsing Remitting Multiple Sclerosis
Start: 2016-06-13End: 2020-06-15Updated: 2020-11-09
Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
RecruitingNCT02919644
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSCurative Resection, Stage IV Colorectal Cancer
Start: 2016-12-02End: 2031-12-31Target: 19Updated: 2024-09-19

Phase 3

TREg Activation in the Treatment of the PELADE (Alopecia Areata)
CompletedNCT02557074
Centre Hospitalier Universitaire de NiceAlopecia Areata
Start: 2015-12-15End: 2019-12-02Updated: 2026-03-24

Related Papers

Phase <scp>I</scp> study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of <scp>Vγ9Vδ2 T</scp>‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide
American Journal of Hematology2024-01-024 citations
Early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with post-transplant cyclophosphamide: Updated results of a monocentric phase 1 study.
Journal of Clinical Oncology2023-06-01
A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
2023-05-2817 citations
Early In Vivo Generation of Vγ9Vδ2 T Cells after Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide: A Monocentric Phase 1 Study
Blood2022-11-15